From:  Targeted therapeutic management of diabetes using phytoconstituents: molecular mechanisms, evidence map (2015–2025), and translational outlook

 Molecular pathways and representative biomarkers.

Molecular pathwayKey biomarkers/targets (examples)Study count (n)
PI3K/AKTIRS-1, AKT, p-AKT, GSK3β, IGF-1, GLUT479
GLUT transportersGLUT2, GLUT4, SGLT235
AMPKACC, SIRT1, PGC-1α, CPT1, LKB125
Other pathwaysPPARγ, adiponectin, FABP4, NF-κB, TNF-α, IL-6, NLRP3, STAT3, MAPK, ER stress, oxidative stress markers, apoptosis38

ACC: acetyl-CoA carboxylase; AMPK: AMP-activated protein kinase; CPT1: carnitine palmitoyltransferase 1; ER: endoplasmic reticulum; FABP4: fatty acid-binding protein 4; GLUT: glucose transporter; GSK3β: glycogen synthase kinase 3 beta; IGF-1: insulin-like growth factor-1; IL-6: interleukin-6; IRS-1: insulin receptor substrate 1; LKB1: liver kinase B1; MAPK: mitogen-activated protein kinase; NF-κB: nuclear factor kappa-light-chain-enhancer of activated B cells; PGC-1α: peroxisome proliferator-activated receptor gamma coactivator 1-alpha; PI3K/AKT: phosphoinositide 3-kinase/protein kinase B; PPARγ: peroxisome proliferator-activated receptor gamma; SGLT2: sodium-glucose cotransporter 2; SIRT1: sirtuin 1; STAT3: signal transducer and activator of transcription 3; TNF-α: tumor necrosis factor-alpha.